Research and Markets has announced the addition of the "Blood Screening Market by Technology (Nucleic Acid Amplification, (rPCR), ELISA, (CLIA, Fluorescence assay), Rapid Test, NGS, Western Blotting), Product (Instrument, Reagent & Kits, Software) & End User - Global Forecasts to 2021" report to their offering.

The market is expected to reach USD 2.80 Billion by 2021 from USD 1.76 Billion in 2016, at a CAGR of 9.7%.

The major factors driving the growth of this market are increasing number of blood donations and blood donors and rising awareness regarding the safety of donated blood. In addition, increasing affordability and adoption of nucleic acid test (NAT) for blood screening, rising demand for donated blood, and increasing prevalence of infectious diseases are also driving the growth of this market.

However, capital expenditure and the operating costs of NAT instruments, lack of mandates for NAT in developing countries, and the emergence of alternative technologies are restraining market growth. Furthermore, some of the major opportunities observed in this market include growing economies such as China and India, the emergence of pathogen reduction technology, and demand of multiplex tests.

Market Dynamics

Drivers

  • Increasing Number of Blood Donations And Blood Donors
  • Increasing Demand of Donated Blood
  • Rising Prevalence of Infectious Diseases
  • Growing Affordability And Adoption of Nat for Blood Screening
  • Rising Awareness Regarding the Safety of Donated Blood

Restraints

  • Capital Expenditure And Operating Costs of Nat
  • Lack of Regulations Mandating the Use of Nat in Developing Countries
  • Emergence of Alternative Technologies

Opportunities

  • Pathogen Reduction Technology
  • Multiplex Tests
  • Emerging Economies

Challenges

  • Price Reduction

Companies Mentioned

  • Abbott Laboratories
  • Beckman Coulter (A Subsidiary of Danaher Corporation)
  • Becton, Dickinson And Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux
  • F. Hoffmann-La Roche
  • Grifols
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers (A Subsidiary of Siemens Ag)
  • Thermo Fisher Scientific, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/f5hjv9/blood_screening